HDAC9 and B-cell non-Hodgkin lymphoma: Hence, this review focuses on discussing the possible mechanisms by which B-cell lymphomas acquire immunotherapy resistance and the effects of HDAC inhibitors on tumor cells and immune cells that could help overcome immunotherapy resistance (Fig. 1).